皓宸医疗：预计2025年全年每股收益亏损:0.0833元至0.1666元

Core Viewpoint - Haocen Medical is expected to report a loss per share of between 0.0833 yuan and 0.1666 yuan for the full year of 2025, primarily due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring items was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a year-on-year decrease of 15.72% [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -966,000 yuan, down 107.53% year-on-year [2]. Cost and Profitability - The company faced significant declines in profitability due to a substantial drop in comprehensive customer unit price [2]. - The debt ratio stood at 71.72%, indicating a high level of financial leverage [2]. - The gross profit margin was reported at 47.72%, reflecting the company's ability to maintain some level of profitability despite revenue declines [2]. Impairment and Valuation - The company plans to recognize goodwill impairment based on a cautious principle, following a goodwill impairment test [2]. - Additionally, the company will conduct impairment tests on long-term equity investments, expecting that the recoverable amounts of some investments will be lower than their book values, leading to further impairment provisions [2].